Feb 2, 2015
|
Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
|
Dec 1, 2014
|
Ardelyx Appoints Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer
|
Nov 17, 2014
|
Ardelyx's Tenapanor Reduces Phosphorus Absorption and Protects against Vascular Calcification in Preclinical In Vivo Model of Chronic Kidney Disease
|
Nov 6, 2014
|
Ardelyx Reports Third Quarter 2014 Financial Results
|
Oct 30, 2014
|
Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014
|
Oct 23, 2014
|
Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
|
Oct 1, 2014
|
Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients
|
Sep 5, 2014
|
Ardelyx Chief Scientific Officer, Dominique Charmot, Announces Retirement from the Company at Year-End
|
Aug 7, 2014
|
Ardelyx Reports Second Quarter 2014 Financial Results
|
Aug 5, 2014
|
Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
|